3 unchanged sentences
Our Insider Trading Policy permits our executive officers and directors to enter into trading plans designed to comply with Rule 10b5-1.
−Removed: During the three-month period ending June 30, 2025 neither we nor any of our executive officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
+Added: The following table describes contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended (each a "Rule 10b5-1 Plan") adopted by our executive officers and directors during the three month period ending September 30, 2025:
+Added: Name and Title Title
+Added: Date of Adoption Duration of Rule 10b5-1 Plan Aggregate Number of Securities to be Purchased Pursuant to the Rule 10b5-1 Plan Aggregate Number of Securities to be Sold Pursuant to the Rule 10b5-1 Plan
+Added: Mukund Paravasthu Chief Operating Officer
+Added: July 29, 2025 11/4/2025-9/30/2026
+Added: 87,894 102,334
+Added: Kinyip Gabriel Leung Director
+Added: August 19, 2025 11/18/2025-8/31/2026
+Added: 24,413 88,410
+Added: During the three-month period ending September 30, 2025, Mr.
+Added: Paravasthu terminated the plan referenced above on September 11, 2025 and none of our other executive officers or directors terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
EXHIBIT INDEX
1 unchanged sentence
Exhibit Description Form Date Number
−Removed: 10.1 2025 NovoCure Employee Share Purchase Plan#
31.1 Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended
14 unchanged sentences
NovoCure Limited
−Removed: July 24, 2025 /s/ Christoph Brackmann
+Added: October 30, 2025 /s/ Christoph Brackmann
Christoph Brackmann
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.